Kenneth J. Pienta, M.D.
Professor of Internal Medicine and of Urology
Director of Experimental Therapeutics, Michigan Center for Translational Pathology
Principal Investigator, Specialized Program of Research Excellence in Prostate Cancer
Prostate Cancer Metastasis and Therapeutic Strategies
Work in Kenneth Pienta’s laboratory focuses on understanding the biology of prostate cancer metastasis — how cancer cells interact with normal cells of the body as they develop a primary tumor and then spread to other sites in the body. He studies this interaction between the normal cells and the cancer cells using principles borrowed from the science of ecology, and believes that by thinking of tumors as ecosystems we can better understand how to treat cancer. His laboratory has especially focused on studying how cancer cells metastasize to bone and to target the resulting metastatic tumors for therapy.
A central question in cancer biology, diagnosis and treatment remains how cancers have the ability to invade and survive in the bone marrow. Pienta and his colleagues believe that metastatic prostate cancers behave like an invasive species attacking a new environment and target and compete with hematopoietic stem cells — cells that reside in bone marrow that make a person’s red and white blood cells — for space in the bone marrow where the hematopoietic cells normally reside. Disseminated tumor cells can hide in marrow for years — where they slowly proliferate — and where humans are slowly and secretly losing the cancer battle.
This is a powerful new observation that opens up entire new biologic questions in understanding cancer metastasis, suggests new diagnostic and prognostic biomarkers, and points to new targets for therapy - all actively being worked on in the laboratory.
Stem cell symposium set for Sept. 19 in Ann Arbor
Dr. Eva Feldman will be among the speakers at the one-day event, which focuses on cutting-edge developments in stem-cell biology, epigenetics and regneratrive medicine.
Click here for details and registration.
New Emerging Scholar named
Scott Tomlins, M.D., an assistant profesor of pathology at U-M, has been designated the A. Alfred Taubman Emerging Scholar. Dr. Tomlins is an expert in prostate cancer research.
People who care
Institute welcomes new gift officer
Maria Muller has been appointed to work with connect donors with funding opportunities at the Taubman Institute.
Click here to read more.
news & events
Institute symposium set for Oct. 10
The A. Alfred Taubman Medical Research Institute will award the 2014 $100,000 Taubman Prize for Excellence in Translational Medical Science at its 7th annual symposium at 10 a.m. on Oct. 10.
Dr. Carl June, a physician-scientist who developed a personalized immunotherapy for leukemia using patients’ own T cells, will receive the honor and deliver the symposium's keynote address.
Click here for symposium details.
Drug cuts risk of bone-marrow transplant side effect
Taubman Emerging Scholar Sung Won Choi, M.D., is the lead author of a new study that finds a new way to help prevent graft-vs-host disease in cancer patients receiving bone-marrow transplants.
Study: Two types of cancer stem cells lead to metastasis
Breast cancer stem cells exist in two different states and each state plays a role in how cancer spreads, according to a new study published by Taubman Senior Scholar Dr. Max Wicha.